{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:29:06Z","timestamp":1776382146772,"version":"3.51.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004429","name":"University of Crete","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Metastastic disease affects up to 50% of colorectal cancer (CRC) patients and is associated with particularly poor outcomes in the presence of the <jats:italic>BRAF<\/jats:italic> V600E mutation. Herein, we report a patient with initial diagnosis of stage IIIc CRC, who presented during follow-up (adjuvant phase) with dysphagia, left-sided lagophthalmos and multiple skin nodules. The ensuing work-up revealed disseminated metastatic disease from the primary CRC, which was <jats:italic>BRAF<\/jats:italic> V600E-mutated (retrospective tissue analysis), affecting, besides the lungs, multiple uncommon sites, such as the skin and parotid gland. The patient\u2019s rapid disease progression did not allow for any therapeutic interventions. This is only the second report of concomitant metastatic infiltration of the skin and parotid gland by CRC, and the first with a documented molecular background of <jats:italic>BRAF<\/jats:italic> V600E mutation. <jats:italic>BRAF<\/jats:italic> V600E-mutated CRC can follow an aggressive and often unpredictable clinical course in the metastatic setting that physicians should be aware of, and the molecular profile of the tumor at diagnosis could be useful for comprehensive and timely management.<\/jats:p>","DOI":"10.3389\/fonc.2025.1512000","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:11:13Z","timestamp":1738041073000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case report: a rare case of diffusely metastatic BRAF V600E-mutated colorectal cancer with concomitant infiltration of the skin and parotid gland"],"prefix":"10.3389","volume":"15","author":[{"given":"Aristeidis E.","family":"Boukouris","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Kokkinakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Drakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Sfakianaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Tzardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Souglakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605694","article-title":"BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients\u2019 outcome","volume":"102","author":"Saridaki","year":"2010","journal-title":"Br J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605164","article-title":"Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer","volume":"101","author":"Souglakos","year":"2009","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_349561","article-title":"The evolving treatment landscape in BRAF-V600E\u2013mutated metastatic colorectal cancer","author":"Tabernero","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v13.i12.2129","article-title":"BRAF(V600E) mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs","volume":"13","author":"Zhi","year":"2021","journal-title":"World J Gastrointest Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2024.04.004","article-title":"BRAF(V600E)-mutant metastatic colorectal cancer: current evidence, future directions, and research priorities","volume":"23","author":"Piercey","year":"2024","journal-title":"Clin Colorectal Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e84604","DOI":"10.1371\/journal.pone.0084604","article-title":"BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients\u2019 outcome","volume":"8","author":"Saridaki","year":"2013","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2018.1433322","article-title":"Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer","volume":"57","author":"Christensen","year":"2018","journal-title":"Acta Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000102538","article-title":"Concomitant occurrence of facial cutaneous and parotid gland metastases from rectal cancer after preoperative chemoradiotherapy","volume":"30","author":"Nasti","year":"2007","journal-title":"Onkologie"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.v109:10","article-title":"Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas","volume":"109","author":"Erickson","year":"2007","journal-title":"Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S282593","article-title":"Cutaneous metastasis as the first presentation of non-small-cell lung cancer with a BRAF mutation: A case report","volume":"13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2213","article-title":"Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1alpha and -2alpha in colon cancer","volume":"69","author":"Kikuchi","year":"2009","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3312","article-title":"Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma","volume":"67","author":"Kumar","year":"2007","journal-title":"Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.86","article-title":"BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer","volume":"23","author":"Zerilli","year":"2010","journal-title":"Mod Pathol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e14541","DOI":"10.14814\/phy2.14541","article-title":"How best to interpret measures of levels of oxygen in tissues to make them effective clinical tools for care of patients with cancer and other oxygen-dependent pathologies","volume":"8","author":"Swartz","year":"2020","journal-title":"Physiol Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"104574","DOI":"10.1016\/j.critrevonc.2024.104574","article-title":"Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts\u2019\u00a0position paper","volume":"206","author":"Malapelle","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"113321","DOI":"10.1016\/j.ejca.2023.113321","article-title":"Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer","volume":"194","author":"Rasola","year":"2023","journal-title":"Eur J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0154795","DOI":"10.1371\/journal.pone.0154795","article-title":"Prognostic role of BRAF mutation in stage II\/III colorectal cancer receiving curative resection and adjuvant chemotherapy: A meta-analysis based on randomized clinical trials","volume":"11","author":"Zhu","year":"2016","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"103696","DOI":"10.1016\/j.esmoop.2024.103696","article-title":"Efficacy and safety of the combination of encorafenib\/cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: an AGEO real-world multicenter study","volume":"9","author":"Gallois","year":"2024","journal-title":"ESMO Open"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1512000\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:11:16Z","timestamp":1738041076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1512000\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1512000"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1512000","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]},"article-number":"1512000"}}